ALB and chronic kidney disease: Compared with the inception of study period (2013/14; Table 4), significant relative change in the fiscal year 2021/22 were found in the quality indicator of annual foot examination (adjusted 12.1% increase; 95% CI, 0.2% to 24.0%; p = 0.048), annual urine dipstick test and/or UACR measurement (adjusted 12.1% increase; 95% CI, 1.7% to 24.0%; p = 0.048), and use of ACEI/ARB therapy for persons with CKD or urine albumin excretion >30 mg/24 h (or equivalent) (adjusted 22.2% increase; 95% CI, 4.5% to 39.9%; p = 0.025).